All In Biotech

NDA 212045 · Hikma

Kloxxado

Naloxone Hydrochloride · Nasal

Last checked: Nov 19, 2026Latest source record: Aug 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Apr 29, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

682

129 Phase 3, 31 recruiting

FAERS reports

861

543 serious, 102 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 25, 2025.

KLOXXADO is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients. KLOXXADO is intended for immediate administration as emergency therapy in settings where opioids may be present. KLOXXADO is not a substitute for emergency medical care. KLOXXADO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients. (1) KLOXXADO is intended for immediate administration as emergency therapy in settings where opioids may be present. KLOXXADO is not a substitute for emergency medical care. ( 1 )

Mechanism: Naloxone hydrochloride is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites. Administration of naloxone hydrochloride reverses the effects of opioids, including respiratory depression, sedation and hypotension. It can also reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 25, 2025 Supplement 5 · Efficacy LetterLabel
  • Apr 29, 2021 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
2 products under this application
  • KLOXXADO · NALOXONE HYDROCHLORIDE 8MG/SPRAY · SPRAY, NASAL · Prescription · TE AB
  • KLOXXADO · NALOXONE HYDROCHLORIDE 4MG/SPRAY · SPRAY, NASAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Naloxone" as an intervention, any sponsor and status, largest first.

All 682 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue91
  • nausea76
  • drug ineffective65
  • headache58
  • pain53
  • diarrhoea52
  • off label use51
  • death48
  • dyspnoea48
  • product dose omission issue48
  • asthenia38
  • rash36

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20054
20063
20071
20081
20096
20115
201215
20131
20143
20153
201610
201719
201835
201941
202049
202128
2022104
2023123
2024131
2025157
2026119

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Kloxxado (Naloxone HCl)

2024 spending

$364K

Beneficiaries

1,848

2,886 claims

Per beneficiary

$197

$59.60 per unit

View as table
YearSpending
2020$0
2021$24,658
2022$354,553
2023$312,278
2024$363,786

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,733 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.